Literature DB >> 15591511

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.

E V Loftus1, G C Harewood, C G Loftus, W J Tremaine, W S Harmsen, A R Zinsmeister, D A Jewell, W J Sandborn.   

Abstract

BACKGROUND: Inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD) may have a high prevalence of rectal sparing, backwash ileitis, and colorectal neoplasia. AIMS: To describe the clinical features and outcomes of PSC-IBD and compare these to a group of chronic ulcerative colitis (CUC) patients.
METHODS: The medical records of all patients with PSC-IBD evaluated at the Mayo Clinic Rochester between 1987 and 1992 were abstracted for information on endoscopic and histological features, colorectal neoplasia, surgery, and other clinical outcomes. Patients referred for colorectal neoplasia and those who did not undergo colonoscopy with biopsies were excluded. A control group of CUC patients matched for sex, duration of IBD at first clinic visit, and calendar year of first clinic visit was identified, and similar information was abstracted.
RESULTS: Seventy one PSC-IBD patients and 142 CUC patients without PSC were identified. Rectal sparing and backwash ileitis were more common in the PSC-IBD group (52% and 51%, respectively) than in controls (6% and 7%, respectively). Overall, colorectal neoplasia developed in 18 cases and 15 controls, including 11 cancers (seven cases and four controls). An increased risk of colorectal neoplasia or death was not detected in a matched analysis. Although the cumulative incidence of colorectal neoplasia was higher in cases (33%) than in controls (13%) at five years, this was of borderline statistical significance (p=0.054, unmatched log rank test). Overall survival from first clinic visit was significantly worse among cases (79% v 97%) at five years (p<0.001, unmatched log rank test).
CONCLUSION: PSC-IBD is frequently characterised by rectal sparing and backwash ileitis. Colorectal neoplasia develops in a substantial fraction and overall survival is worse. PSC-IBD may represent a distinct IBD phenotype.

Entities:  

Mesh:

Year:  2005        PMID: 15591511      PMCID: PMC1774346          DOI: 10.1136/gut.2004.046615

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

Authors:  Darrell S Pardi; Edward V Loftus; Walter K Kremers; Jill Keach; Keith D Lindor
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study.

Authors:  K W Nuako; D A Ahlquist; W J Sandborn; D W Mahoney; D M Siems; A R Zinsmeister
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

3.  Primary sclerosing cholangitis: a long-term follow-up study.

Authors:  E Aadland; E Schrumpf; O Fausa; K Elgjo; A Heilo; T Aakhus; E Gjone
Journal:  Scand J Gastroenterol       Date:  1987-08       Impact factor: 2.423

4.  Controlled clinical trials: the controls are the key.

Authors:  D J Ahnen
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

5.  Primary sclerosing cholangitis: findings on cholangiography and pancreatography.

Authors:  R L MacCarty; N F LaRusso; R H Wiesner; J Ludwig
Journal:  Radiology       Date:  1983-10       Impact factor: 11.105

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.

Authors:  C Penna; R Dozois; W Tremaine; W Sandborn; N LaRusso; C Schleck; D Ilstrup
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

9.  Cholangiocarcinoma complicating primary sclerosing cholangitis.

Authors:  C B Rosen; D M Nagorney; R H Wiesner; R J Coffey; N F LaRusso
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

10.  Risk factors of colorectal cancer in inflammatory bowel disease.

Authors:  P Bansal; A Sonnenberg
Journal:  Am J Gastroenterol       Date:  1996-01       Impact factor: 10.864

View more
  173 in total

Review 1.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification.

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Fumihiro Okumura; Katsuyuki Miyabe; Michihiro Yoshida; Hiroaki Yamashita; Hirotaka Ohara; Takashi Joh
Journal:  J Gastroenterol       Date:  2011-09-23       Impact factor: 7.527

3.  Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study.

Authors:  Wei Gong; Nonghua Lv; Bangmao Wang; Ye Chen; Yinglong Huang; Wenshen Pan; Bo Jiang
Journal:  Dig Dis Sci       Date:  2011-09-22       Impact factor: 3.199

Review 4.  Diagnosis of IgG4-related sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Katsuyuki Miyabe; Shuya Simizu; Takashi Joh
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 6.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623

7.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

8.  Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  J Crohns Colitis       Date:  2014-02-19       Impact factor: 9.071

9.  Inflammatory bowel disease: one or two diseases?

Authors:  David B Sachar; Aaron Walfish
Journal:  Curr Gastroenterol Rep       Date:  2013-01

10.  Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Harry Sokol; Jacques Cosnes; Olivier Chazouilleres; Laurent Beaugerie; Emmanuel Tiret; Raoul Poupon; Philippe Seksik
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.